ECSP12011793A - Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, método para la preparación de los mismos y composición farmacéutica que los contiene - Google Patents
Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, método para la preparación de los mismos y composición farmacéutica que los contieneInfo
- Publication number
- ECSP12011793A ECSP12011793A ECSP12011793A ECSP12011793A EC SP12011793 A ECSP12011793 A EC SP12011793A EC SP12011793 A ECSP12011793 A EC SP12011793A EC SP12011793 A ECSP12011793 A EC SP12011793A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutical composition
- oxidase
- xantina
- inhibitors
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a nuevos compuestos que son eficaces como un inhibidor para la xantina-oxidasa, a un proceso para preparar los mismos y a una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20090095363 | 2009-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP12011793A true ECSP12011793A (es) | 2012-05-30 |
Family
ID=43857261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP12011793 ECSP12011793A (es) | 2009-10-07 | 2012-03-23 | Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, método para la preparación de los mismos y composición farmacéutica que los contiene |
Country Status (27)
Country | Link |
---|---|
US (1) | US8729273B2 (es) |
EP (1) | EP2467378B1 (es) |
JP (1) | JP5702392B2 (es) |
KR (1) | KR101751325B1 (es) |
CN (1) | CN102574839B (es) |
AP (1) | AP3346A (es) |
AR (1) | AR078504A1 (es) |
AU (1) | AU2010304091B2 (es) |
BR (1) | BR112012007828B8 (es) |
CA (1) | CA2774133C (es) |
CL (1) | CL2012000738A1 (es) |
CO (1) | CO6430501A2 (es) |
EA (1) | EA021025B1 (es) |
EC (1) | ECSP12011793A (es) |
ES (1) | ES2599829T3 (es) |
HK (1) | HK1170224A1 (es) |
IL (1) | IL218669A (es) |
MA (1) | MA33880B1 (es) |
MX (1) | MX2012003782A (es) |
MY (1) | MY162813A (es) |
PE (1) | PE20121088A1 (es) |
SG (1) | SG179186A1 (es) |
TR (1) | TR201203989T1 (es) |
TW (1) | TWI423962B (es) |
UA (1) | UA110197C2 (es) |
WO (1) | WO2011043568A2 (es) |
ZA (1) | ZA201202544B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI548630B (zh) * | 2011-04-06 | 2016-09-11 | Lg生命科學有限公司 | 1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-羧酸結晶型及其製造方法 |
CA2844128C (en) * | 2011-08-30 | 2020-09-01 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
ME03055B (me) | 2013-03-29 | 2018-10-20 | Teijin Pharma Ltd | Derivat pirazola |
AU2015289492B2 (en) | 2014-07-17 | 2020-02-20 | Chdi Foundation, Inc. | Methods and compositions for treating HIV-related disorders |
CN104774172B (zh) * | 2015-04-08 | 2017-03-22 | 河南师范大学 | 一种3‑氰基吲哚类化合物的合成方法 |
AU2016316278B2 (en) * | 2015-09-02 | 2020-06-04 | Sunshine Lake Pharma Co., Ltd. | Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof |
CN106008488B (zh) * | 2016-05-20 | 2018-10-30 | 广东东阳光药业有限公司 | 氰基吲哚类衍生物及其制备方法和用途 |
WO2018157801A1 (zh) * | 2017-02-28 | 2018-09-07 | 广东东阳光药业有限公司 | 氰基取代的稠合双环衍生物及其制备方法和用途 |
CA3100308C (en) * | 2018-06-01 | 2024-02-20 | Autophagysciences Inc. | Compound and pharmaceutical composition comprising the same |
CN111072647B (zh) * | 2019-12-11 | 2021-02-26 | 沈阳药科大学 | 3-取代吲哚-5-氧代-4,5-二氢-1,2,4-噁二唑类化合物及其用途 |
CN111072634B (zh) * | 2020-01-03 | 2022-07-22 | 中国医科大学 | 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用 |
US20240000750A1 (en) | 2020-11-04 | 2024-01-04 | Lg Chem, Ltd. | Method for preparing crystalline particles of 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid, and pharmaceutical composition comprising same |
KR20220077091A (ko) | 2020-12-01 | 2022-06-08 | 주식회사 엘지화학 | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 안정한 경구용 제제 |
JP2023551524A (ja) | 2020-12-01 | 2023-12-08 | エルジー・ケム・リミテッド | 1-(3-シアノ-1-イソプロピル-インドール-5-イル)ピラゾール-4-カルボン酸を含む経口用製剤、およびその製造方法 |
CN112920170B (zh) * | 2021-01-29 | 2023-06-20 | 中国医科大学 | N-(吲哚-5-基)芳香杂环酰胺类化合物及其制备方法和用途 |
JP2024511899A (ja) | 2021-04-16 | 2024-03-15 | エルジー・ケム・リミテッド | 1-(3-シアノ-1-イソプロピル-インドール-5-イル)ピラゾール-4-カルボン酸を含む経口用製剤 |
WO2022231262A1 (ko) * | 2021-04-27 | 2022-11-03 | 주식회사 엘지화학 | 잔틴 옥시다아제 저해제의 제조 방법 |
WO2022231263A1 (ko) * | 2021-04-27 | 2022-11-03 | 주식회사 엘지화학 | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 |
KR20220147529A (ko) * | 2021-04-27 | 2022-11-03 | 주식회사 엘지화학 | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 |
WO2022233264A1 (zh) | 2021-04-29 | 2022-11-10 | 江苏新元素医药科技有限公司 | 一类黄嘌呤氧化酶抑制剂 |
AU2022294728A1 (en) | 2021-06-15 | 2024-01-04 | Lg Chem, Ltd. | Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid |
AR126164A1 (es) | 2021-06-17 | 2023-09-27 | Lg Chemical Ltd | Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico |
TWI822151B (zh) | 2021-07-02 | 2023-11-11 | 南韓商Lg化學股份有限公司 | 製備黃嘌呤氧化酶抑制劑的方法 |
WO2023277658A1 (ko) | 2021-07-02 | 2023-01-05 | 주식회사 엘지화학 | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 |
CN116715633A (zh) * | 2022-04-27 | 2023-09-08 | 江苏新元素医药科技有限公司 | 可用于降尿酸的化合物 |
WO2023208103A1 (zh) * | 2022-04-27 | 2023-11-02 | 江苏新元素医药科技有限公司 | 可用于痛风的化合物 |
CN116283946B (zh) * | 2023-03-27 | 2024-05-07 | 武汉工程大学 | 5-(n-取代吲哚-5-基)异噁唑-3-甲酸衍生物及其合成方法和应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU218942B (hu) | 1990-11-30 | 2001-01-29 | Teijin Ltd. | 2-Fenil-tiazol-származékok, az ezeket tartalmazó gyógyászati készítmények, valamint eljárás a vegyületek előállítására |
ID21775A (id) | 1996-10-25 | 1999-07-22 | Yoshitomi Pharmaceutical | Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya |
US6635640B2 (en) * | 2000-06-30 | 2003-10-21 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
ES2250422T3 (es) * | 2000-07-10 | 2006-04-16 | Bristol-Myers Squibb Company | Composicion y actividad antiviral de derivados de piperazina indoloxoaceticos sustituidos. |
WO2008011131A2 (en) * | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
AU2003249535A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
EP1911760A4 (en) * | 2005-07-01 | 2010-06-02 | Nippon Chemiphar Co | xanthine oxidase inhibitor |
BRPI0616939A2 (pt) * | 2005-10-07 | 2011-07-05 | Astellas Pharma Inc | derivado de ácido triarilacarboxìlico |
US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
JP2008179621A (ja) * | 2006-12-28 | 2008-08-07 | Taisho Pharmaceutical Co Ltd | 含窒素飽和複素環化合物 |
WO2008126770A1 (ja) | 2007-04-05 | 2008-10-23 | Astellas Pharma Inc. | トリアリールカルボン酸誘導体の製造方法 |
CN101679251B (zh) * | 2007-04-11 | 2013-10-02 | 橘生药品工业株式会社 | (氮杂)吲哚衍生物及其医药用途 |
US8227500B2 (en) | 2007-04-11 | 2012-07-24 | Kissei Pharmaceutical Co., Ltd. | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same |
EP2338887A4 (en) * | 2008-10-15 | 2012-05-09 | Kissei Pharmaceutical | FUSIONED HETEROCYCLIC DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES |
JP5688660B2 (ja) | 2008-10-16 | 2015-03-25 | オートマチック バー コントロールス インコーポレイテッド | 食物製品のオンデマンド分配のための機器および方法およびターンテーブル |
US8785489B2 (en) * | 2008-10-17 | 2014-07-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as MMP-13 inhibitors |
WO2011036130A1 (en) * | 2009-09-24 | 2011-03-31 | F. Hoffmann-La Roche Ag | Indole derivatives as crac modulators |
-
2010
- 2010-10-01 TW TW099133473A patent/TWI423962B/zh active
- 2010-10-04 SG SG2012018768A patent/SG179186A1/en unknown
- 2010-10-04 EP EP10822213.4A patent/EP2467378B1/en active Active
- 2010-10-04 TR TR2012/03989T patent/TR201203989T1/xx unknown
- 2010-10-04 AU AU2010304091A patent/AU2010304091B2/en active Active
- 2010-10-04 WO PCT/KR2010/006760 patent/WO2011043568A2/en active Application Filing
- 2010-10-04 KR KR1020100096578A patent/KR101751325B1/ko active IP Right Grant
- 2010-10-04 PE PE2012000438A patent/PE20121088A1/es active IP Right Grant
- 2010-10-04 MX MX2012003782A patent/MX2012003782A/es active IP Right Grant
- 2010-10-04 US US13/498,253 patent/US8729273B2/en active Active
- 2010-10-04 EA EA201270520A patent/EA021025B1/ru unknown
- 2010-10-04 CN CN201080044868.1A patent/CN102574839B/zh active Active
- 2010-10-04 MY MYPI2012700104A patent/MY162813A/en unknown
- 2010-10-04 JP JP2012533074A patent/JP5702392B2/ja active Active
- 2010-10-04 UA UAA201204342A patent/UA110197C2/ru unknown
- 2010-10-04 ES ES10822213.4T patent/ES2599829T3/es active Active
- 2010-10-04 AP AP2012006191A patent/AP3346A/xx active
- 2010-10-04 BR BR112012007828A patent/BR112012007828B8/pt active IP Right Grant
- 2010-10-04 MA MA34731A patent/MA33880B1/fr unknown
- 2010-10-04 CA CA2774133A patent/CA2774133C/en active Active
- 2010-10-05 AR ARP100103609A patent/AR078504A1/es active IP Right Grant
-
2012
- 2012-03-15 IL IL218669A patent/IL218669A/en active IP Right Grant
- 2012-03-23 CO CO12049241A patent/CO6430501A2/es active IP Right Grant
- 2012-03-23 CL CL2012000738A patent/CL2012000738A1/es unknown
- 2012-03-23 EC ECSP12011793 patent/ECSP12011793A/es unknown
- 2012-04-10 ZA ZA2012/02544A patent/ZA201202544B/en unknown
- 2012-10-30 HK HK12110873.7A patent/HK1170224A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP12011793A (es) | Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, método para la preparación de los mismos y composición farmacéutica que los contiene | |
CY1125155T1 (el) | Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης | |
CR20140361A (es) | Inhibidores de pde9 con estructura básica de imidazotriazinona | |
WO2010093191A3 (en) | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | |
CO6362015A2 (es) | Derivados de acido 1-amino-2ciclobutiletilboronico | |
CR20120317A (es) | Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a | |
GT201400063A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
BR112012027509A8 (pt) | Composto pirazolil-quinoxalina inibidor de quinase, combinação, produto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e método | |
UY33735A (es) | Compuestos antivirales | |
CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
UY35467A (es) | Compuestos orgánicos | |
CO6761389A2 (es) | Inhibidores de nampt y rock | |
MY165087A (en) | Neprilysin inhibitors | |
UY34917A (es) | Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación | |
ECSP10010434A (es) | Inhibidores de hsp90 | |
EP2582812A4 (en) | NOVEL PHARMACEUTICAL FORMS WITH MODIFIED RELEASE OF XANTHINE OXYDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS | |
CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
CR20120319A (es) | Derivados de fenilimidazol heteroaromáticos como inhibidores de enzima pde10a | |
BR112013016241A2 (pt) | composto, e, método para fabricar um composto | |
CU24263B1 (es) | Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer | |
CL2012002506A1 (es) | Compuestos derivados de heterociclos sustituidos, inhibidores de la enzima pde10; composiciones farmacéuticas que comprenden dichos compuestos; y un método para tratar desórdenes neurológicos en un animal de sangre caliente, tal como esquizofrenia. | |
ECSP14004595A (es) | 2-tiopirimidinonas | |
EA201270280A1 (ru) | Соединения пиримидина в качестве ингибиторов при лечении туберкулеза | |
CL2014000289A1 (es) | Compuestos derivados de 3,4-dihidro-1h-[1,8]naftiridonas sustituidas, inhibidores de la actividad de la enzima fabl; proceso para preparar dichos compuestos; composicion farmaceutica que los comprende; y proceso para preparar esta composicion farmaceutica. | |
CO6321288A2 (es) | Sales de compuestos inhibidores de vih |